SWOG clinical trial number
SWOG-9212
Phase II Trial of Oral Etoposide in Recurrent or Refractory Endometrial Adenocarcinoma
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Trial of Oral Etoposide in Recurrent or Refractory Endometrial Adenocarcinoma
Activated
05/15/1994
Closed
01/15/1997
Research committees
Gynecologic Cancer
Publication Information Expand/Collapse
1999
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: A Southwest Oncology Group study
1998
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma (SWOG 9212).